Literature DB >> 6446789

Allogeneic tolerance in embryo aggregation mouse chimeras studied by mixed lymphocyte culture and cell-mediated lympholysis.

T Matsunaga, E Simpson, T Meo.   

Abstract

Tolerance in embryo aggregation (EA) mouse chimeras was investigated using mixed lymphocyte culture (MLC) reaction and cell-mediated lympholysis (CML). In most cases, spleen or lymph node cells from EA chimeras were specifically unresponsive toward their parental cells in both MLC and CML. There was no evidence to support the involvement of "serum-blocking factors" or suppressor cells under these experimental conditions. There was, however, an exceptional chimera in which cytotoxic T cell percursors reactive against one parental cell may have been present. We argue for classical clonal elimination being the primary mechanism for tolerance in EA chimeras and discuss a role of suppressor mechanisms for self-tolerance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446789     DOI: 10.1097/00007890-198007000-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Functional clonal deletion of cytotoxic T-lymphocyte precursors in chimeric thymus produced in vitro from embryonic Anlagen.

Authors:  M F Good; K W Pyke; G J Nossal
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

2.  The phenotype of lymphoid cells and thymic epithelium correlates with development of autoimmune insulitis in NOD in equilibrium with C57BL/6 allophenic chimeras.

Authors:  S Forsgren; U Dahl; A Söderström; D Holmberg; T Matsunaga
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

3.  "A Japanese gentleman of the Samurai tradition": Takeshi Matsunaga 1945-2003.

Authors:  Francesco Colucci; Elizabeth Simpson; Anne McLaren; Satoshi Hayakawa; Elisabet Andersson; Lucia Mincheva-Nilsson; Vladimir Baranov
Journal:  Immunogenetics       Date:  2003-10-14       Impact factor: 2.846

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.